Born and raised in Dayton, Ohio, Dr. Amol Soin’s journey into the medical field began after completing high school in Beavercreek. He embarked on a challenging but rewarding path at the University of Akron, where he was part of a combined 6-year BS/MD medical school program.
His early years were marked by a strong work ethic and a keen interest in research, leading him to publish the book “Curing America: A Look Inside America’s Failing Health Care System” when he was 19. This work highlighted the plight of the 40 million Americans (1997) without health insurance, despite the country’s vast economic resources.
Dr. Soin’s medical training continued at Rush University in Chicago, where he specialized in anesthesiology and further honed his research skills, particularly in pain management. His residency was followed by a fellowship at the Cleveland Clinic, one of the United States’ most prestigious pain management departments. Here, Dr. Soin mastered advanced pain management techniques and contributed to the field through research and publications.
Over the years, Dr. Soin has developed numerous technologies – drugs as well as medical devices. Most recently, in 2022, he sold Soin Therapeutics to a publicly traded company on NASDAQ for $30 million. “It was super cool because when we closed the deal they announced it on times square in NYC on the NASDAQ building,” he recalls.
Soin Neuroscience and Soin BioScience
With a vision to address the opioid crisis in Montgomery County, Dr. Soin founded two companies: Soin Neuroscience and Soin BioScience, biotech startups dedicated to developing non-opioid solutions for pain management.
Witnessing the staggering statistics of addiction and overdose deaths, Dr. Soin realized the urgent need for alternative pain management solutions. “I started it after realizing people are dying of opioid overdoses because we don’t have great alternatives to treat pain without addiction,” he reflects. His mission was clear: to develop better, non-addictive ways to treat pain.
The company’s notable achievements include the development of a novel type of spinal cord stimulator (Soin Neuroscience) and a gel patch (Soin BioScience), both innovative approaches to pain relief. The spinal cord stimulator uses customized electrical signals to block pain signals in the spinal cord, while the gel patch offers a convenient and effective method for delivering pain medication.
Dr. Soin’s work has not only contributed to the advancement of pain management but also provided hope for countless individuals suffering from chronic pain.
A Personal Experience
Dr. Soin’s commitment to his mission is further illustrated by his personal clinical experiences. One such experience involves Tyrone, a former college athlete from Southwest Ohio. Tyrone suffered from a severe nerve disorder that resulted in excruciating leg pain, to the point where he couldn’t even touch his leg. After enduring this pain for 20 years, Tyrone turned to Dr. Soin for help.
Under Dr. Soin’s care, Tyrone received treatment with Soin Neuroscience’s novel and experimental spinal cord stimulator, which delivers a complex waveform to block pain signals. The results were nothing short of miraculous. “We delivered our proprietary complex waveform and his pain dropped to 0,” Dr. Soin recounts. The moment Tyrone could touch his leg for the first time in years was profoundly moving, with his wife breaking down in tears over the phone. This story, among others, underscores the profound impact that Dr. Soin’s work can have or has had on individuals’ lives. This short YouTube link shows Tyrone’s and others story of pain dropping to 0 with this new device: Click Here.
Talking about his work, innovations, and accomplishments, he passionately mentions “The key is to always put the patient’s experience first. If you spend all your time and efforts focusing on that, then you are bound to do well.”
Spinal Cord Stimulator: A Customized Approach to Pain Relief
Invented by Dr Amol Soin and Dr Eric Schepis, Soin Neuroscience’s new spinal cord stimulator is a marvel in the field of pain management. It operates through a surgically inserted lead placed directly on the spinal cord, equipped with multiple electrodes that transmit electrical signals to block pain signals. This process, known as neuromodulation, alters the firing of pain signals, offering patients significant relief.
What truly distinguishes this device is its approach to signaling. Traditional spinal cord stimulators emit basic signals, akin to blips or beeps. In contrast, Soin Neuroscience has pioneered the use of complex electrical signals, akin to delivering harmonious symphonies to the nerves. This innovative approach was inspired by the realization that certain sounds, much like musical compositions, are more pleasing than others. By converting spinal cord stimulation signals into a form of noise, the team at Soin Neuroscience has been able to identify and deliver signals that are not only effective but also more agreeable to the patient.
One of the most groundbreaking aspects of this technology is the use of a frequency of energy that echoes through every atom in the universe, known as the “primordial sound of the universe.” This frequency, believed to be significant in the creation event, has shown remarkable results in making pain virtually disappear when applied to the spinal cord.
Dr. Soin has shared insights into this technology through a concise two-minute video on YouTube, which provides a helpful overview of how the spinal cord stimulator works and the principles behind its success: YouTube Video: Spinal Cord Stimulator.
By harnessing complex electrical signalsand crafting customized tuned signals specific and unique to each patient, Soin Neuroscience is not only advancing the field of pain management but also offering hope to countless individuals suffering from chronic pain.
Gel Patch: A Discreet and Versatile Pain Solution
In addition to the spinal cord stimulator, Soin BioScience has developed the “gel patch,” a unique pain relief solution that applies like a gel and dries clear and functions like a pain patch. Unlike traditional topical medications, the gel patch is water-resistant and can continuously deliver medication for 6-8 hours. Its innovative formulation allows for targeted application, making it ideal for treating a variety of pains, including joint pain, arthritis, and back pain.
These products demonstrate Soin BioScience’s commitment to developing non-opioid pain relief options that are both effective and patient friendly. By focusing on personalized treatment and innovative delivery methods, the company is making significant strides in improving the quality of life for those suffering from chronic pain.
Navigating the Challenges of the Biotech Industry
Dr. Amol Soin is acutely aware of the hurdles faced by the biotech industry, particularly in the realm of pain management and medical innovation. He outlines several key challenges that impact the development and adoption of new medical technologies.
- Price Controls: He expresses concern about potential price controls on pharmaceuticals, which could limit the financial upside for new innovations. “This may have downward pressure on innovation,” he explains, emphasizing the high costs of development and the risk of not being able to recoup those expenses.
- Regulatory Hurdles: The FDA approval process is another significant barrier, characterized by its expense and time-consuming nature. Dr. Soin highlights the necessity of rigorous studies for patient safety but acknowledges the challenges they present for getting products to market.
- Complexity of Clinical Trials: Pain, being a subjective symptom, adds another layer of complexity to clinical trials. Dr. Soin notes the reliance on patient-reported outcomes, which can be more challenging to quantify and validate compared to objective measures.
- David vs. Goliath: The dominance of large multinational corporations in the biotech industry presents a daunting challenge for startups like Soin Neuroscience and Soin BioSceince. The transformational leader articulates the threat of being overshadowed or crushed by these giants, especially if their products pose a disruptive threat.
- Insurance Companies: Finally, he points out the reluctance of insurance companies to cover new, potentially superior treatments due to cost considerations. He criticizes the preference for covering cheaper, narcotic painkillers despite their addictive nature and lack of efficacy in addressing the root cause of pain.
Through his insights, Dr. Soin sheds light on the multifaceted challenges that innovators in the biotech industry face, emphasizing the need for a supportive ecosystem that fosters innovation and patient-centric solutions.
Leaving a Lasting Legacy
Dr. Soin’s commitment to innovation and patient care extends beyond his clinical practice. He has served in various leadership roles, including as President of the American Society of Interventional Pain Physicians, The Ohio Society of Interventional Pain Physicians andthe State Medical Board of Ohio. His contributions to the field have been recognized through multiple awards, including being named one of America’s Top Doctors in Pain Management and receiving the Patient’s Choice Award (Ohio Pain Clinic).
Today, Dr. Soin continues to lead the way in pain management as the medical director of the Ohio Pain Clinic. His work not only addresses the immediate needs of patients but also contributes to the broader efforts to combat opioid addiction and improve healthcare accessibility in the United States.
Talking about his vision going forward, Dr. Soin concludes saying “I am excited to continue bringing-in new innovative technologies to the market.”
Visit Soin Neuroscience Website.
Read Digital Magazine of this Issue.
Contact Dr. Amol Soin on LinkedIn.
